-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Genmab Reports Rina-S Showed 45.9% ORR, 9.5-Month mPFS And 12.1-Month mDOR In Platinum-Resistant Ovarian Cancer, With Activity Regardless Of FRα Expression Levels

Benzinga·10/05/2026 06:56:09
Listen to the news
  • Treatment with Rina-S 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resistant ovarian cancer (PROC)
  • Antitumor activity was observed regardless of folate receptor alpha (FRα) expression levels, including low FRα expression and non-expressors